Extended Data Fig. 9: Improved survival of patients in the TCGA database with high Notch ligand and low Rubicon expression.
From: Exclusion of Notch from the contact site during efferocytosis restricts anticancer immunity
Kaplan-Meier survival curves obtained from all TCGA solid tumor studies (n = 10720). (a and b) Survival outcomes in patients with low (bottom 25%) or high (top 25%) expression of Rubicon and high (a) or low (b) expression of DLL1. (cand d) Survival outcomes in patients with low (bottom 25%) or high (top 25%) expression of Rubicon and high (c) or low (d) expression of DLL4. (e and f) Survival outcomes in patients with low (bottom 25%) or high (top 25%) expression of Rubicon and high (e) or low (f) expression of JAG1. (g and h) Survival outcomes in patients with low (bottom 25%) or high (top 25%) expression of Rubicon and high (g) or low (h) expression of JAG2. Statistical significance evaluated using the Log-rank test.
